Boehringer Ingelheim GmbH signed a licensing deal potentially worth more than $7 billion with China’s Sino Biopharmaceutical Limited and its subsidiaries for experimental cancer treatments, according to Bloomberg.
Article
Boehringer Ingelheim, Sino Biopharmaceutical Sign Cancer Drug License Deal Worth Over $7 Billion
--・